Initiation: Multiple price inflections on clinical pipeline
Cerulean is on track to announce critical Phase II trial results for CRLX101 in metastatic renal cancer (mRCC) in H116 following encouraging preliminary efficacy data in a Phase IIa readout presented at ASCO in 2015. Additionally, interim Phase Ib/II results are due for CRLX101 in ovarian and rectal cancers in H215 and Phase I data for CRLX301 in 2015 in solid tumors. If positive, these results should renew confidence in Cerulean’s pipeline and its differentiated nanoparticle drug conjugate technology (NDC). We value Cerulean at $273m ($10.0 per share).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.